Clinical development, registration, and introduction of human rotavirus vaccine: The Latin American experience
Autor(a) principal: | |
---|---|
Data de Publicação: | 2012 |
Outros Autores: | , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Digital do Instituto Evandro Chagas (Patuá) |
Texto Completo: | https://patua.iec.gov.br/handle/iec/3266 |
Resumo: | Rotavirus (RV) is the leading cause of severe gastroenteritis (GE) among infants and young children worldwide, accounting for 453,000 deaths in children aged <5 years. In Latin America rotavirus causes an estimated 15,000 deaths annually and accounts for 20–70% of acute gastroenteritis cases requiring hospitalization. This results in an estimated annual cost of approximately US$86 million. The most common G type has been G1 (∼50%), followed by G4, G3 and G9, although regional and temporal variations are significant. There are currently two effective rotavirus vaccines: a single-strain, human attenuated-based (RotarixTM, GlaxoSmithKline Biologicals), and a five-strain, bovine-human reassortant vaccine (RotaTeqTM, Merck and Company). The pioneering strategy behind the development and licensure of RotarixTM was part of a new paradigm for global vaccine research and development focusing on introduction first in countries with greatest medical needs. Rotarix™ demonstrated high efficacy and a good safety profile in Phase II and III clinical trials performed in Latin America. In the pivotal phase III study involving 11 Latin American countries a 2-year efficacy of 81% (95% CI: 71–87) was achieved against severe rotavirus acute gastroenteritis. A high protective efficacy was observed against severe rotavirus gastroenteritis caused by G1 and non-G1 strains. RotarixTM proved to be safe regarding intussusception (IS) in a two-dose vaccine schedule beginning at 6–12 weeks of age. First registered in Mexico in July 2004, Rotarix™ gained World Health Organization (WHO) prequalification in February 2007 and has been introduced for routine use into the universal mass vaccination programs of Brazil, Panama, Mexico, Venezuela, Ecuador, Guatemala, Honduras, Colombia, Paraguay, Bolivia, Peru, and El Salvador. The main factors influencing the decision-making process of introducing rotavirus vaccines in Latin American countries included: (a) demonstration of good efficacy/safety profiles; (b) political decision to decrease mortality; (c) decision from ministries of health; (d) availability of data on the disease burden; (e) cold chain available; and, importantly (f) the use of PAHO's Revolving Fund for the purchase of vaccines. Post-licensure studies have shown 76% (95% CI: 64–84%) effectiveness in El Salvadoran children and 76% (95% CI: 58–86%) to 85% (95% CI: 53–94%) in Brazil. Observational studies in Panama, Mexico, El Salvador and Brazil reported reduction in all-cause diarrhea-related hospitalizations at rates of 22–37%, 11–40%, 35–48%, and 17–48%, respectively. The decline in diarrhea-associated deaths reached 35% (95% CI: 29–39%) in Mexico and ranged from 22% (95% CI: 6–45%) to 33% (95% CI: 15–52%) among Brazilian children. A low, increased risk of intussusception was detected among Mexican infants within 7 days after first vaccine dose [odds ratio, 5.8 (95% CI: 2.6–13)]. Continuous and expanding post-licensure rotavirus surveillance studies are needed to better assess the effect of universal vaccination in Latin American countries and elsewhere. |
id |
IEC-2_67bd5c78fdd54a7a632c65131cbf79d8 |
---|---|
oai_identifier_str |
oai:patua.iec.gov.br:iec/3266 |
network_acronym_str |
IEC-2 |
network_name_str |
Repositório Digital do Instituto Evandro Chagas (Patuá) |
repository_id_str |
|
spelling |
Schael, Irene PerezO'Ryan, MiguelSáez-Llorens, XavierLinhares, Alexandre da CostaVelázquez, F. RColindres, Romulo EBreuer, ThomasOrtega-Barria, Eduardo2018-07-19T12:33:11Z2018-07-19T12:33:11Z2012SCHAEL, Irene Perez et al. Clinical development, registration, and introduction of human rotavirus vaccine: The Latin American experience. Trials in Vaccinology, v. 1, p. 10-20, 2012.1879-4378https://patua.iec.gov.br/handle/iec/326610.1016/j.trivac.2012.01.001Rotavirus (RV) is the leading cause of severe gastroenteritis (GE) among infants and young children worldwide, accounting for 453,000 deaths in children aged <5 years. In Latin America rotavirus causes an estimated 15,000 deaths annually and accounts for 20–70% of acute gastroenteritis cases requiring hospitalization. This results in an estimated annual cost of approximately US$86 million. The most common G type has been G1 (∼50%), followed by G4, G3 and G9, although regional and temporal variations are significant. There are currently two effective rotavirus vaccines: a single-strain, human attenuated-based (RotarixTM, GlaxoSmithKline Biologicals), and a five-strain, bovine-human reassortant vaccine (RotaTeqTM, Merck and Company). The pioneering strategy behind the development and licensure of RotarixTM was part of a new paradigm for global vaccine research and development focusing on introduction first in countries with greatest medical needs. Rotarix™ demonstrated high efficacy and a good safety profile in Phase II and III clinical trials performed in Latin America. In the pivotal phase III study involving 11 Latin American countries a 2-year efficacy of 81% (95% CI: 71–87) was achieved against severe rotavirus acute gastroenteritis. A high protective efficacy was observed against severe rotavirus gastroenteritis caused by G1 and non-G1 strains. RotarixTM proved to be safe regarding intussusception (IS) in a two-dose vaccine schedule beginning at 6–12 weeks of age. First registered in Mexico in July 2004, Rotarix™ gained World Health Organization (WHO) prequalification in February 2007 and has been introduced for routine use into the universal mass vaccination programs of Brazil, Panama, Mexico, Venezuela, Ecuador, Guatemala, Honduras, Colombia, Paraguay, Bolivia, Peru, and El Salvador. The main factors influencing the decision-making process of introducing rotavirus vaccines in Latin American countries included: (a) demonstration of good efficacy/safety profiles; (b) political decision to decrease mortality; (c) decision from ministries of health; (d) availability of data on the disease burden; (e) cold chain available; and, importantly (f) the use of PAHO's Revolving Fund for the purchase of vaccines. Post-licensure studies have shown 76% (95% CI: 64–84%) effectiveness in El Salvadoran children and 76% (95% CI: 58–86%) to 85% (95% CI: 53–94%) in Brazil. Observational studies in Panama, Mexico, El Salvador and Brazil reported reduction in all-cause diarrhea-related hospitalizations at rates of 22–37%, 11–40%, 35–48%, and 17–48%, respectively. The decline in diarrhea-associated deaths reached 35% (95% CI: 29–39%) in Mexico and ranged from 22% (95% CI: 6–45%) to 33% (95% CI: 15–52%) among Brazilian children. A low, increased risk of intussusception was detected among Mexican infants within 7 days after first vaccine dose [odds ratio, 5.8 (95% CI: 2.6–13)]. Continuous and expanding post-licensure rotavirus surveillance studies are needed to better assess the effect of universal vaccination in Latin American countries and elsewhere.GlaxoSmithKline (GSK) Biologicals was the funding source and was involved in all stages of the study conduct and analysis. GSK Biologicals also funded all costs associated with the development and the publishing of the present manuscript.Ministerio de Salud. Universidad Central de Venezuela. Instituto de Biomedicina. Retired Investigator. Carmelitas, Caracas, Venezuela.University of Chile. Faculty of Medicine. Institute of Biomedical Sciences. Santiago, Chile.Hospital del Niño. Ciudad de Panamá, Panama.Ministério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas. Belém, PA, Brasil.Instituto Mexicano del Seguro Social. CMN-SXXI. Pediatrics Hospital. Medical Research Unit on Infectious Diseases. México City, México.GlaxoSmithKline Biologicals. Rio de Janeiro, RJ, Brazil.GlaxoSmithKline Biologicals. Rixensart, Belgium.engElsevierClinical development, registration, and introduction of human rotavirus vaccine: The Latin American experienceinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleRotavirusVacinas contra Rotavirus / provisão & distribuiçãoAmérica Latinainfo:eu-repo/semantics/openAccessreponame:Repositório Digital do Instituto Evandro Chagas (Patuá)instname:Instituto Evandro Chagas (IEC)instacron:IECORIGINALClinical development, registration, and introduction of human rotavirus vaccine: The Latin American experience.pdfClinical development, registration, and introduction of human rotavirus vaccine: The Latin American experience.pdfapplication/pdf421860https://patua.iec.gov.br/bitstreams/932f5437-bb31-47c7-b532-59d01b62454b/download2cddc8d86a1f5db2a22c5e8a20e6aadbMD51LICENSElicense.txtlicense.txttext/plain; charset=utf-871https://patua.iec.gov.br/bitstreams/0c58e935-d826-42b4-8520-e39cdfe368a1/download52f1732ea66fbd1123abe39f5373b797MD52TEXTClinical development, registration, and introduction of human rotavirus vaccine: The Latin American experience.pdf.txtClinical development, registration, and introduction of human rotavirus vaccine: The Latin American experience.pdf.txtExtracted texttext/plain80118https://patua.iec.gov.br/bitstreams/6d2a50f2-d455-4b6c-aac3-d4aafc327a10/downloadf64c632348f9539d8ffa1f7820a873adMD55THUMBNAILClinical development, registration, and introduction of human rotavirus vaccine: The Latin American experience.pdf.jpgClinical development, registration, and introduction of human rotavirus vaccine: The Latin American experience.pdf.jpgGenerated Thumbnailimage/jpeg5639https://patua.iec.gov.br/bitstreams/a8f766fc-5d4f-4455-a355-75994e5640f5/downloadf5cef071de8ba2b91b2eff384011e174MD56iec/32662022-10-20 23:40:54.53oai:patua.iec.gov.br:iec/3266https://patua.iec.gov.brRepositório InstitucionalPUBhttps://patua.iec.gov.br/oai/requestclariceneta@iec.gov.br || Biblioteca@iec.gov.bropendoar:2022-10-20T23:40:54Repositório Digital do Instituto Evandro Chagas (Patuá) - Instituto Evandro Chagas (IEC)falseVG9kb3Mgb3MgZG9jdW1lbnRvcyBkZXNzYSBjb2xlw6fDo28gc2VndWVtIGEgTGljZW7Dp2EgQ3JlYXRpdmUgY29tbW9ucy4= |
dc.title.pt_BR.fl_str_mv |
Clinical development, registration, and introduction of human rotavirus vaccine: The Latin American experience |
title |
Clinical development, registration, and introduction of human rotavirus vaccine: The Latin American experience |
spellingShingle |
Clinical development, registration, and introduction of human rotavirus vaccine: The Latin American experience Schael, Irene Perez Rotavirus Vacinas contra Rotavirus / provisão & distribuição América Latina |
title_short |
Clinical development, registration, and introduction of human rotavirus vaccine: The Latin American experience |
title_full |
Clinical development, registration, and introduction of human rotavirus vaccine: The Latin American experience |
title_fullStr |
Clinical development, registration, and introduction of human rotavirus vaccine: The Latin American experience |
title_full_unstemmed |
Clinical development, registration, and introduction of human rotavirus vaccine: The Latin American experience |
title_sort |
Clinical development, registration, and introduction of human rotavirus vaccine: The Latin American experience |
author |
Schael, Irene Perez |
author_facet |
Schael, Irene Perez O'Ryan, Miguel Sáez-Llorens, Xavier Linhares, Alexandre da Costa Velázquez, F. R Colindres, Romulo E Breuer, Thomas Ortega-Barria, Eduardo |
author_role |
author |
author2 |
O'Ryan, Miguel Sáez-Llorens, Xavier Linhares, Alexandre da Costa Velázquez, F. R Colindres, Romulo E Breuer, Thomas Ortega-Barria, Eduardo |
author2_role |
author author author author author author author |
dc.contributor.author.fl_str_mv |
Schael, Irene Perez O'Ryan, Miguel Sáez-Llorens, Xavier Linhares, Alexandre da Costa Velázquez, F. R Colindres, Romulo E Breuer, Thomas Ortega-Barria, Eduardo |
dc.subject.decsPrimary.pt_BR.fl_str_mv |
Rotavirus Vacinas contra Rotavirus / provisão & distribuição América Latina |
topic |
Rotavirus Vacinas contra Rotavirus / provisão & distribuição América Latina |
description |
Rotavirus (RV) is the leading cause of severe gastroenteritis (GE) among infants and young children worldwide, accounting for 453,000 deaths in children aged <5 years. In Latin America rotavirus causes an estimated 15,000 deaths annually and accounts for 20–70% of acute gastroenteritis cases requiring hospitalization. This results in an estimated annual cost of approximately US$86 million. The most common G type has been G1 (∼50%), followed by G4, G3 and G9, although regional and temporal variations are significant. There are currently two effective rotavirus vaccines: a single-strain, human attenuated-based (RotarixTM, GlaxoSmithKline Biologicals), and a five-strain, bovine-human reassortant vaccine (RotaTeqTM, Merck and Company). The pioneering strategy behind the development and licensure of RotarixTM was part of a new paradigm for global vaccine research and development focusing on introduction first in countries with greatest medical needs. Rotarix™ demonstrated high efficacy and a good safety profile in Phase II and III clinical trials performed in Latin America. In the pivotal phase III study involving 11 Latin American countries a 2-year efficacy of 81% (95% CI: 71–87) was achieved against severe rotavirus acute gastroenteritis. A high protective efficacy was observed against severe rotavirus gastroenteritis caused by G1 and non-G1 strains. RotarixTM proved to be safe regarding intussusception (IS) in a two-dose vaccine schedule beginning at 6–12 weeks of age. First registered in Mexico in July 2004, Rotarix™ gained World Health Organization (WHO) prequalification in February 2007 and has been introduced for routine use into the universal mass vaccination programs of Brazil, Panama, Mexico, Venezuela, Ecuador, Guatemala, Honduras, Colombia, Paraguay, Bolivia, Peru, and El Salvador. The main factors influencing the decision-making process of introducing rotavirus vaccines in Latin American countries included: (a) demonstration of good efficacy/safety profiles; (b) political decision to decrease mortality; (c) decision from ministries of health; (d) availability of data on the disease burden; (e) cold chain available; and, importantly (f) the use of PAHO's Revolving Fund for the purchase of vaccines. Post-licensure studies have shown 76% (95% CI: 64–84%) effectiveness in El Salvadoran children and 76% (95% CI: 58–86%) to 85% (95% CI: 53–94%) in Brazil. Observational studies in Panama, Mexico, El Salvador and Brazil reported reduction in all-cause diarrhea-related hospitalizations at rates of 22–37%, 11–40%, 35–48%, and 17–48%, respectively. The decline in diarrhea-associated deaths reached 35% (95% CI: 29–39%) in Mexico and ranged from 22% (95% CI: 6–45%) to 33% (95% CI: 15–52%) among Brazilian children. A low, increased risk of intussusception was detected among Mexican infants within 7 days after first vaccine dose [odds ratio, 5.8 (95% CI: 2.6–13)]. Continuous and expanding post-licensure rotavirus surveillance studies are needed to better assess the effect of universal vaccination in Latin American countries and elsewhere. |
publishDate |
2012 |
dc.date.issued.fl_str_mv |
2012 |
dc.date.accessioned.fl_str_mv |
2018-07-19T12:33:11Z |
dc.date.available.fl_str_mv |
2018-07-19T12:33:11Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
SCHAEL, Irene Perez et al. Clinical development, registration, and introduction of human rotavirus vaccine: The Latin American experience. Trials in Vaccinology, v. 1, p. 10-20, 2012. |
dc.identifier.uri.fl_str_mv |
https://patua.iec.gov.br/handle/iec/3266 |
dc.identifier.issn.-.fl_str_mv |
1879-4378 |
dc.identifier.doi.-.fl_str_mv |
10.1016/j.trivac.2012.01.001 |
identifier_str_mv |
SCHAEL, Irene Perez et al. Clinical development, registration, and introduction of human rotavirus vaccine: The Latin American experience. Trials in Vaccinology, v. 1, p. 10-20, 2012. 1879-4378 10.1016/j.trivac.2012.01.001 |
url |
https://patua.iec.gov.br/handle/iec/3266 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
Elsevier |
publisher.none.fl_str_mv |
Elsevier |
dc.source.none.fl_str_mv |
reponame:Repositório Digital do Instituto Evandro Chagas (Patuá) instname:Instituto Evandro Chagas (IEC) instacron:IEC |
instname_str |
Instituto Evandro Chagas (IEC) |
instacron_str |
IEC |
institution |
IEC |
reponame_str |
Repositório Digital do Instituto Evandro Chagas (Patuá) |
collection |
Repositório Digital do Instituto Evandro Chagas (Patuá) |
bitstream.url.fl_str_mv |
https://patua.iec.gov.br/bitstreams/932f5437-bb31-47c7-b532-59d01b62454b/download https://patua.iec.gov.br/bitstreams/0c58e935-d826-42b4-8520-e39cdfe368a1/download https://patua.iec.gov.br/bitstreams/6d2a50f2-d455-4b6c-aac3-d4aafc327a10/download https://patua.iec.gov.br/bitstreams/a8f766fc-5d4f-4455-a355-75994e5640f5/download |
bitstream.checksum.fl_str_mv |
2cddc8d86a1f5db2a22c5e8a20e6aadb 52f1732ea66fbd1123abe39f5373b797 f64c632348f9539d8ffa1f7820a873ad f5cef071de8ba2b91b2eff384011e174 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Digital do Instituto Evandro Chagas (Patuá) - Instituto Evandro Chagas (IEC) |
repository.mail.fl_str_mv |
clariceneta@iec.gov.br || Biblioteca@iec.gov.br |
_version_ |
1787533075477954560 |